HIV and malaria co-infection: interactions and consequences of chemotherapy

Trends in Parasitology

Volumn 24, Issue 6, 2008, Pages 264-271

  Skinner Adams, T S ^a,b   McCarthy, J S ^a,b   Gardiner, D L ^b   Andrews, K T ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMODIAQUINE; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ARTEMISININ; ARTESUNATE; ATAZANAVIR; CHLOROQUINE; COTRIMOXAZOLE; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; MEFLOQUINE; NEVIRAPINE; PIPERAQUINE; PRIMAQUINE; PROTEINASE INHIBITOR; PYRIMETHAMINE; QUININE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; SULFADOXINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG EFFICACY; DRUG METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INCIDENCE; INFECTION RISK; LIVER TOXICITY; MALARIA; MALARIA CONTROL; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; REVIEW; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTI-HIV AGENTS; ANTIMALARIALS; COMORBIDITY; DRUG DESIGN; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MALARIA;

EID: 43949084669     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2008.03.008     Document Type: Review

References (74)

1. Hay S.I., et al. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect. Dis. 4 (2004) 327-336
2. Ashley E., et al. Malaria. Travel Med. Infect. Dis. 4 (2006) 159-173
3. Lalloo D.G., et al. Malaria in adolescence: burden of disease, consequences, and opportunities for intervention. Lancet Infect. Dis. 6 (2006) 780-793
4. UNAIDS/WHO AIDS Epidemic Update December 2006. UNAIDS/WHO. Available at http://data.unaids.org/pub/Epireport/2006/2006EpiUpdate_en.pdf
5. World Health Organization. (2004) Malaria and HIV interactions and their implications for Public Health Policy. WHO, Geneva, Switzerland
6. Kamya M.R., et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J. Infect. Dis. 193 (2006) 9-15
7. Whitworth J., et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 356 (2000) 1051-1056
8. ter Kuile F.O., et al. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 297 (2007) 2603-2616
9. Griffith K.S., et al. Treatment of malaria in the United States: a systematic review. JAMA 297 (2007) 2264-2277
10. Brentlinger P.E., et al. Prevalence and predictors of maternal peripheral malaria parasitemia in central Mozambique. Am. J. Trop. Med. Hyg. 77 (2007) 228-234
11. van Eijk A.M., et al. Effectiveness of intermittent preventative treatment with sulphadoxine-pyrimethamine for the control of malaria in pregnancy in western Kenya: a hospital based study. Trop. Med. Int. Health 9 (2004) 351-360
12. Gonsalez C.R., et al. Drug resistance among chronic HIV-1-infected patients naive for use of anti-retroviral therapy in Sao Paulo city. Virus Res. 129 (2007) 87-90
13. Peuchant O., et al. Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antivir. Ther. 12 (2007) 559-562
14. HIV treatment access reaches over 1 million in sub-Saharan Africa, WHO report. Available at www.who.int/mediacentre/news/releases/2006/pr38/en/index.html
15. Zachariah R., and Massaquoi M. Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries. Trop. Doct. 36 (2006) 79-82
16. Watera C., et al. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. J. Acquir. Immune Defic. Syndr. 42 (2006) 373-378
17. Jelinek T., et al. Plasmodium falciparum: selection of serine 108 of dihydrofolate reductase during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children. Am. J. Trop. Med. Hyg. 61 (1999) 125-130
18. McIntyre J. Maternal health and HIV. Reprod. Health Matters 13 (2005) 129-135
19. Okereke C.S. Management of HIV-infected pregnant patients in malaria-endemic areas: therapeutic and safety considerations in concomitant use of antiretroviral and antimalarial agents. Clin. Ther. 21 (1999) 1456-1496
20. Grimwade K., et al. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 18 (2004) 547-554
21. Otieno R.O., et al. Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria. AIDS 20 (2006) 275-280
22. Hoffman I.F., et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 13 (1999) 487-494
23. ter Kuile F.O., et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am. J. Trop. Med. Hyg. 71 (2004) 41-54
24. Holmes C.B., et al. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin. Infect. Dis. 36 (2003) 652-662
25. Van Geertruyden J.P., et al. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J. Infect. Dis. 194 (2006) 917-925
26. Abu-Raddad L.J., et al. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 314 (2006) 1603-1606
27. Lucas S.B., et al. Disease in children infected with HIV in Abidjan, Cote d'Ivoire. Br. Med. J. 312 (1996) 335-338
28. Newton C.R. Interaction between Plasmodium falciparum and human immunodeficiency virus type 1 on the central nervous system of African children. J. Neurovirol. 11 Suppl. 3 (2005) 45-51
29. Inion I., et al. Placental malaria and perinatal transmission of human immunodeficiency virus type 1. J. Infect. Dis. 188 (2003) 1675-1678
30. Mount A.M., et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 363 (2004) 1860-1867
31. Pisell T.L., et al. Immune activation and induction of HIV-1 replication within CD14 macrophages during acute Plasmodium falciparum malaria coinfection. AIDS 16 (2002) 1503-1509
32. Chaisavaneeyakorn S., et al. Immunity to placental malaria. III. Impairment of interleukin (IL)-12, not IL-18, and interferon-inducible protein-10 responses in the placental intervillous blood of human immunodeficiency virus/malaria-coinfected women. J. Infect. Dis. 185 (2002) 127-131
33. Xiao L., et al. Plasmodium falciparum antigen-induced human immunodeficiency virus type 1 replication is mediated through induction of tumor necrosis factor-alpha. J. Infect. Dis. 177 (1998) 437-445
34. Nathoo S., et al. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet 362 (2003) 1039-1041
35. Owen A., et al. In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J. Pharmacol. Exp. Ther. 314 (2005) 1202-1209
36. German P., et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin. Infect. Dis. 44 (2007) 889-891
37. Gasasira A.F., et al. High risk of neutropenia in HIV infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin. Infect. Dis. 46 (2008) 985-991
38. German, P. et al. (2008) Drug interaction between antimalarial drugs and Lopinavir/Ritonavir. 15th conference on retroviruses and opportunistic infections, Boston USA. Available at wwwretroconference.org/2008/pdfs/132.pdf
39. Savarino A., et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 15 (2001) 2221-2229
40. Savarino A., et al. The anti-HIV-1 activity of chloroquine. J. Clin. Virol. 20 (2001) 131-135
41. Skinner-Adams T.S., et al. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 51 (2007) 759-762
42. Savarino A., et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J. Acquir. Immune Defic. Syndr. 35 (2004) 223-232
43. Khoo S., et al. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 19 (2005) 995-1005
44. Plosker G.L., and Scott L.J. Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs 63 (2003) 1299-1324
45. Lefevre G., et al. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur. J. Pharm. Sci. 10 (2000) 141-151
46. Svensson U.S., and Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br. J. Clin. Pharmacol. 48 (1999) 528-535
47. Khaliq Y., et al. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br. J. Clin. Pharmacol. 51 (2001) 591-600
48. Lucia M.B., et al. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J. Acquir. Immune Defic. Syndr. 39 (2005) 635-637
49. Pajonk F., et al. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res. 62 (2002) 5230-5235
50. Reed M.B., et al. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403 (2000) 906-909
51. Sidhu A.B., et al. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol. Microbiol. 57 (2005) 913-926
52. Sidhu A.B., et al. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 194 (2006) 528-535
53. Price R.N., et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364 (2004) 438-447
54. Skinner-Adams T.S., et al. Antiretrovirals as antimalarial agents. J. Infect. Dis. 190 (2004) 1998-2000
55. Parikh S., et al. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 49 (2005) 2983-2985
56. Redmond A.M., et al. Antimalarial activity of sera from subjects taking HIV protease inhibitors. AIDS 21 (2007) 763-765
57. Andrews K.T., et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob. Agents Chemother. 50 (2006) 639-648
58. Savarino A., et al. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors. J. Infect. Dis. 191 (2005) 1381-1382
59. Skinner-Adams T., et al. Reply to Savarino. J. Infect. Dis. 191 (2005) 1382-1383
60. Omara-Opyene A.L., et al. Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J. Biol. Chem. 279 (2004) 54088-54096
61. Liu J., et al. The role of Plasmodium falciparum food vacuole plasmepsins. J. Biol. Chem. 280 (2005) 1432-1437
62. Parikh S., et al. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Antimicrob. Agents Chemother. 50 (2006) 2207-2209
63. Rogerson S. HIV-1, antiretroviral therapy, and malaria. Lancet 362 (2003) 1008-1009
64. + bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production. Hum. Exp. Toxicol. 23 (2004) 173-185
65. Freund Y.R., et al. Synergistic bone marrow toxicity of pyrimethamine and zidovudine in murine in vivo and in vitro models: mechanism of toxicity. Toxicol. Appl. Pharmacol. 181 (2002) 16-26
66. Veal G.J., and Back D.J. Metabolism of Zidovudine. Gen. Pharmacol. 26 (1995) 1469-1475
67. University of Liverpool online database. Drug Interaction Charts. Available at www.hiv-druginteractions.org.
68. Bartlett J.G., and Gallant M.D. 2005-2006 Medical Management of HIV Infection (2005), Johns Hopkins University Medicine Press
69. Tong L., et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51 (2007) 3498-3504
70. HIV and AIDS Treatments Online resource. Available at www.hivandhepatitis.com/hiv_and_aids/prezista_1.html
71. Benakis A., et al. Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am. J. Trop. Med. Hyg. 56 (1997) 17-23
72. Tsai W.P., et al. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res. Hum. Retroviruses 6 (1990) 481-489
73. Giao P.T., and de Vries P.J. Pharmacokinetic interactions of antimalarial agents. Clin. Pharmacokinet. 40 (2001) 343-373
74. Savarino A., et al. Quinoline antimalarials as investigational drugs for HIV-1/AIDS: in vitro effects on HIV-1 replication, HIV-1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations. Drug Dev. Res. 67 (2006) 806-817